|
|
|
|
|
|
|
|
Bill Dolbow,
Director of Field
Operations
Located in: Florida
Mobile: 561-248-3859
Email:
bdolbow@advancedcirculatory.com
|
 |
|
Clinical
Support and Training
Specialists |
|
|
|
Katie Talk,
CCEMTP, NREMT-P; Clinical Support
Specialist
Located in: North
Carolina
Mobile: 910-964-8899
Email:
ktalk@advancedcirculatory.com
VA, NC, SC, GA, FL,
AL, TN, MS |
 |
|
Rob Cinquemani,
MBA, EMT-P; Clinical Support
Specialist
Located in: New York
Mobile: 914-355-0088
Email:
rcinquemani@advancedcirculatory.com
OH, WV, MD, DE, NJ, PA,
CT, RI, MA, NH, ME, VT,
NY, DC |
 |
|
Greg Wolf, EMT-P;
Clinical Support
Specialist
Located in: Texas
Mobile: 281-705-7957
Email:
gwolf@advancedcirculatory.com
MN, IA, MO, AR, LA,
ND, SD, NE, KS, OK, TX,
MT, WY, CO, NM, ID, UT,
AZ, WA, OR, NV, CA, AK,
HI |
 |
|
|
Rick
Pister, Sales
Manager
Located in: California
Mobile: 818-517-7411
Email:
rpister@advancedcirculatory.com
|
 |
|
|
Kristin Weivoda,
NREMT-P, FP-C; Clinical
Support Specialist
Located in: California
Mobile: 805-878-7061
Email:
kweivoda@advancedcirculatory.com
WA, OR,
ID, CA, NV, UT, AZ |
 |
|
|
Cheya
Gerard,
Clinical Educator
Located in: Minnesota
Mobile: 651-246-0530
Email:
cgerard@advancedcirculatory.com
MN |
 |
|
|
|
|
Nancy Theisen,
ResQPOD Product Manager
Located in: Minnesota
Phone: 651-403-5609
Email:
ntheisen@advancedcirculatory.com
|
 |
|
Michael McLaury,
RN; ResQGARD Product
Manager
Located in: Ohio
Mobile: 216-789-2300
Email:
mmclaury@advancedcirculatory.com
|
 |
|
|
|
Headquarters
|
|
|
|
|
|
The generally cleared
indication for the ResQPOD is a temporary increase in blood circulation
during emergency care,
 hospital,
clinic and home use.
Click here to review the Instructions for
Use. Studies are ongoing in the United States to evaluate the
long-term benefit of the ResQPOD for indications related to patients
suffering from cardiac arrest, hypotension during dialysis
and severe blood loss.
For more information on completed
clinical studies click here. The references on this website are not
intended to imply specific outcome-based claims not yet cleared by the
US Food and Drug Administration.
|
|
|
